Evidência dos Modificadores do Sistema Renina-Angiotensina na Prevenção da Enxaqueca Episódica
DOI:
https://doi.org/10.24950/R/190/20/1/2021Palavras-chave:
Inibidores da Enzima Conversora de Angiotensina, Perturbações de Enxaqueca/prevenção e controloResumo
Introdução: A enxaqueca é uma doença frequente e incapacitante. Modelos experimentais sugerem uma relação entre o sistema renina-angiotensina e o desenvolvimento de enxaqueca. Este artigo tem como objetivo rever a evidência dos inibidores deste sistema na redução da frequência dos episódios de enxaqueca.
Métodos: Foi efetuada a pesquisa de normas de orientação clínica (NOC), de revisões sistemáticas (RS) e meta-análises (MA), bem como de ensaios clínicos aleatorizados (ECA). O nível de evidência e forças de recomendação foram atribuídos recorrendo à escala Strength of Recommendation Taxonomy (SORT).
Resultados: Foram identificados 63 artigos, tendo sido selecionados oito: quatro NOC, duas RS/MA e duas RS.
Discussão/Conclusão: O tratamento preventivo da enxaqueca episódica pode ser efetuado com candesartan 16 mg/ dia (FR B), embora ainda não seja recomendado como fármaco de primeira linha. O lisinopril também mostrou potencial na prevenção da enxaqueca episódica (FR B).
Downloads
Referências
Global Burden of Disease 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:954–76
Ha H, Gonzalez A. Migraine headache prophylaxis. Am Fam Physician. 2019;99:17-24.
Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16: 86–92.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2013;33:629-808
Pringsheim T, Davenport WJ, Mackie G, Worthington I, Aubé M, Christie SN, et al. Canadian Headache Society Guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39:S1-59.
Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One. 2015;10:e0130733
Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain. 2019;20:57.
Touche RL, Pérez JJ, Acosta AP, Campodónico LG, García SM, Juárez DA, et al. Is aerobic exercise helpful in patients with migraine? A systematic review and meta-analysis. Scand J Med Sci Sports. 2020;30(6):965-82.
Diener HC, Gendolla A, Feuersenger A, Evers S, Straube A, Schumacher H et al. Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. Cephalalgia. 2009;29:921-7.
Scottish Intercollegiate Guidelines Network (SIGN). Pharmacological management of migraine. Edinburgh: SIGN; 2018. (SIGN publication no. 155). [consultado Jun 2020] Disponível em: http://www.sign.ac.uk
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78: 1337-45.
Dorosch T, Ganzer CA, Lin M, Seifan A. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults. Curr Pain Headache Rep. 2019;23:85.
Ripa P, Omello R, Pistoia F, Carolei A, Sacco S. The renin–angiotensin system: a possible contributor to migraine pathogenesis and prophylaxis. Expert Rev. Neurother. 2014;14:1043–55.
Fusayasu E, Kowa H, Takeshima T, Nakaso K, Nakashima K. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain. 2007;128:209-14.
Adelborg K, Szépligeti SK, Holland-Bill L, Ehrenstein V, Horváth-Puhó E, Henderson VW et al. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ. 2018;360:k96.
Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369:1208-19.
Rist PM, Winter AC, Buring JE, Sesso HD, Kurth T. Migraine and the risk of incident hypertension among women. Cephalalgia 2018;38:1817-24.
Entonen AH, Suominen SB, Korkeila K, Mäntyselkä PT, Sillanmäki LH, Ojanlatva A, et al. Migraine predicts hypertension--a cohort study of the Finnish working-age population. Eur J Public Health. 2014;24:244-8.
Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014;34:523-32
Ebell MH, Siwek J, Weiss BD, Woolf SH, Jeffrey S, Ewingman B, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician. 2004;69:548-56.
Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289:65-9.
Toward Optimized Practice (TOP). Primary care management of headache in adults – Clinical Practice Guideline. Alberta: TOP; 2016. 2nd ed. [consultado Jun 2020] Disponível em: https://actt.albertadoctors.org/CPGs/Lists/CPGDocumentList/Primary-Care-Management-of-Headache-in-Adults.pdf
Schrader H, Stovner LJ, Helde G, Trond Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ. 2001;322: 19.
Sarchielli P, Granella F, Prudenzano MP, Pini LA, Guidetti V, Bono G, et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain. 2012;13:S31-70.
Schuh-Hofer S, Flach U, Meisel A, Israel H, Reuter U, Arnold G. Efficacy of lisinopril in migraine prophylaxis-an open label study. Eur J Neurol. 2007;14:701-3.
Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol. 2009;16:968-81.
Kouremenos E, Arvaniti C, Constantinidis TS, Giannouli E, Fakas N, Kalamatas T et al. Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine J Headache Pain. 2019;20(1),113.
Paterna S, di Pasquale P, Martino S, Arrostuto A, Ingurgio NC, Parrinello G, et al. Captopril versus placebo in the prevention of hemicrania without aura. A randomized double-blind study. Clin Ter. 1992;141:475-81.
Sonbolestan SA, Heshmat K, Javanmard SH, Saadatnia M. Efficacy of enalapril in migraine prophylaxis: a randomized, double-blind, placebo-controlled trial. Int J Prev Med. 2013;4:72-7.
Shamliyan TA, Choi JY, Ramakrishnan R, Miller JB, Wang SY, Taylor FR, et al. Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med. 2013;28:1225-37
Minervini MG, Pinto K. Captopril relieves pain and improves mood depression in depressed patients with classical migraine. Cephalalgia. 1987;7:485–6.
Sassi KLM, Martins LB, de Miranda AS, Teixeira AL. Renin-angiotensin-aldosterone system and migraine: a systematic review of human studies. Protein Pept Lett. 2020;27:512-9.
Montgomery L. Are angiotensin-converting enzyme (ACE) inhibitors effective in preventing migraine in nonhypertensive patients? J Fam Pract. 2001;50:299.
Charles JA, Jotkowitz S, Byrd LH. Prevention of migraine with olmesartan in patients with hypertension/prehypertension. Headache. 2006;46:503-7.
Park H-J, Lee S-T, Kim M. Inhibitory control of angiotensin converting enzyme by ramipril in migraine. Neurol Asia. 2013;18:289–91.
Bessaguet F, Magy L, Desmoulière A, Demiot C. The therapeutic potential of renin angiotensin aldosterone system (RAAS) in chronic pain: from preclinical studies to clinical trials. Expert Rev Neurother. 2016;16:331-9.
Downloads
Publicado
Como Citar
Edição
Secção
Licença
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Direitos de Autor (c) 2023 Medicina Interna
Acesso livre
